COMBINATION THERAPY FOR ADVANCED RESISTANT HODGKIN'S DISEASE
- 20 December 1975
- journal article
- Published by Elsevier in The Lancet
- Vol. 306 (7947), 1224-1227
- https://doi.org/10.1016/s0140-6736(75)92069-3
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomasCancer, 1974
- Combination chemotherapy of advanced Hodgkin's disease.A reviewCancer, 1974
- Combination Chemotherapy in Advanced Hodgkin's DiseaseAnnals of Internal Medicine, 1973
- Early Clinical Experience with Bleomycin in the United Kingdom in Series of 105 PatientsBMJ, 1972
- Bleomycin, an Antitumor AntibioticAnnals of Internal Medicine, 1972
- Treatment of Advanced Hodgkin’s Disease with [1,3 Bis (2-Chloroethyl)-1-Nitrosourea] BCNUNew England Journal of Medicine, 1971
- Combination Chemotherapy in the Treatment of Advanced Hodgkin's DiseaseAnnals of Internal Medicine, 1970
- Combination Chemotherapy in Generalized Hodgkin's DiseaseBMJ, 1970
- BCNU (1,3), BIS(B-chloroethyl)-1-nitrosourea. Effects on advanced Hodgkin's disease and other neoplasiaCancer, 1968
- Alkylating Activity of 1,3-Bis(2-chloroethyl)-1-nitrosourea and Related CompoundsJournal of Medicinal Chemistry, 1967